НАУКОВО-ПРАКТИЧНІ ЗАСАДИ СТВОРЕННЯ ТА ЗАПРОВАДЖЕННЯ ПРЕПАРАТІВ ВПЛИВУ НА ЕНДОКАНАБІНОЇДНУ СИСТЕМУ
PDF

Як цитувати

Хабленко, А., Зубик, П., & Литвинов, Г. (2021). НАУКОВО-ПРАКТИЧНІ ЗАСАДИ СТВОРЕННЯ ТА ЗАПРОВАДЖЕННЯ ПРЕПАРАТІВ ВПЛИВУ НА ЕНДОКАНАБІНОЇДНУ СИСТЕМУ. InterConf, (77). вилучено із https://ojs.ukrlogos.in.ua/index.php/interconf/article/view/14928
PDF

Посилання

Pacher P., Bátkai S., Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy // Pharmacol. Rev. 2006. Vol. 58, № 3. P. 389–462.

Lu H.-C., Mackie K. An Introduction to the Endogenous Cannabinoid System // Biol. Psychiatry. 2016. Vol. 79, № 7. P. 516–525.

Cherkasova V., Kovalchuk O., Kovalchuk I. Cannabinoids and Endocannabinoid System Changes in Intestinal Inflammation and Colorectal Cancer // Cancers (Basel). 2021. Vol. 13, № 17. P. 4353.

Neuroscience / edited by Dale Purves ... [et al.].– 3rd ed.p.; cm. Includes bibliographical references and index. ISBN 0-87893-725-0 (casebound : alk. paper).

Archie S.R., Cucullo L. Harmful Effects of Smoking Cannabis: A Cerebrovascular and Neurological Perspective // Front. Pharmacol. 2019. Vol. 10.

Goyal H., Awad H.H., Ghali J.K. Role of cannabis in cardiovascular disorders // J. Thorac. Dis. 2017. Vol. 9, № 7. P. 2079–2092.

Sheikh NK, Dua A. Cannabinoids. [Updated 2021 Jul 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556062/.

Piscitelli F., Di Marzo V. Cannabinoids: a class of unique natural products with unique pharmacology // Rend. Lincei. Sci. Fis. e Nat. 2021. Vol. 32, № 1. P. 5–15.

Koob G.F., Arends M.A., Le Moal M. Cannabinoids // Drugs, Addiction, and the Brain. Elsevier, 2014. P. 261–308.

Bloemendal V.R.L.J., van Hest J.C.M., Rutjes F.P.J.T. Synthetic pathways to tetrahydrocannabinol (THC): an overview // Org. Biomol. Chem. 2020. Vol. 18, № 17. P. 3203–3215.

Stella B. et al. Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain // Drugs. 2021. Vol. 81, № 13. P. 1513–1557.

Grotenhermen F., Müller-Vahl K. The Therapeutic Potential of Cannabis and Cannabinoids // Dtsch. Aerzteblatt Online. 2012.

Arzimanoglou A. et al. Epilepsy and cannabidiol: a guide to treatment. // Epileptic Disord. 2020. Vol. 22, № 1. P. 1–14.

Thiele E.A. et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. // Lancet (London, England). 2018. Vol. 391, № 10125. P. 1085–1096.

Zajicek J. et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial // Lancet. 2003. Vol. 362, № 9395. P. 1517–1526.

Killestein J. et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS // Neurology. 2002. Vol. 58, № 9. P. 1404–1407.

PETRO D.J., ELLENBERGER C. Treatment of Human Spasticity with Δ 9 -Tetrahydrocannabinol // J. Clin. Pharmacol. 1981. Vol. 21, № S1. P. 413S-416S.

Ungerleider J.T. et al. Delta-9-THC in the Treatment of Spasticity Associated with Multiple Sclerosis // Adv. Alcohol Subst. Abuse. 1988. Vol. 7, № 1. P. 39–50.

Marinol® Product Monograph Available online: https://pdf.hres.ca/dpd_pm/00013378.PDF (accessed March 10, 2021). Syndros Product Monograph Available online.

Cesamet® Product Monograph Available online: https://pdf.hres.ca/dpd_pm/00007760.PDF (accessed March 10, 2021). Sativex® Product Monograph Available online: https://pdf.hres.ca/dpd_pm/00016162.PDF (accessed on 10 March 2021).

Martyn C.., Illis L.., Thom J. Nabilone in the treatment of multiple sclerosis // Lancet. 1995. Vol. 345, № 8949. P. 579.

Hamann W., di Vadi P. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors // Lancet. 1999. Vol. 353, № 9152. P. 560.

Sieradzan K.A. et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study // Neurology. 2001. Vol. 57, № 11. P. 2108–2111.

Fox S.H. et al. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia // Mov. Disord. 2002. Vol. 17, № 1. P. 145–149.

Epidyolex® Summary of Product characteristics Available online: https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf (accessed March 10, 2021).

Sativex® Product Monograph Available online: https://pdf.hres.ca/dpd_pm/00016162.PDF (accessed on 10 March 2021).

Lichtman A.H. et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain // J. Pain Symptom Manage. 2018. Vol. 55, № 2. P. 179-188.e1.

Fallon M.T. et al. Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies // Br. J. Pain. 2017. Vol. 11, № 3. P. 119–133.

Wade D.T. et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients // Mult. Scler. J. 2004. Vol. 10, № 4. P. 434–441.

Mead A. Legal and Regulatory Issues Governing Cannabis and Cannabis-Derived Products in the United States // Front. Plant Sci. 2019. Vol. 10.

The current state of the use of cannabis compounds in the world medical practice (available in Russian): веб-сайт. URL: https://hta.ua/en/activity/analytic/the-current-state-of-the-use-of-cannabis-compounds-in-the-world-medical-practice-available-in-russi.

Що треба знати про епілепсію: веб-сайт. URL: https://phc.org.ua/news/scho-treba-znati-pro-epilepsiyu.

Про внесення змін до переліку наркотичних засобів, психотропних речовин і прекурсорів. Постанова КМУ № 324: веб-сайт. URL: https://www.kmu.gov.ua/npas/pro-vnesennya-zmin-do-pereliku-narkotichnih-zasobiv-psihotropnih-rechovin-i-prekursoriv-i070421-324.

Chouvy P.-A. Cannabis cultivation in the world: heritages, trends and challenges // EchoGéo. 2019. № 48

Creative Commons License

Ця робота ліцензується відповідно до Creative Commons Attribution 4.0 International License.

Завантаження

Дані завантаження ще не доступні.

| Переглядів: 15 | Завантажень: 26 |